Lupin Files Suit to Stop Ranbaxy from Selling Drug in US

06 Apr 2011 Evaluate

Lupin has filed a second suit in the US against Ranbaxy Laboratories to prevent the country’s largest drugmaker from launching fenofibrate, a generic version of Lupin’s cholesterol lowering drug Antara in the US. The second lawsuit pertains to a new patent Lupin received in January from the US patent authority. It has been filed by a Swiss arm of the Mumbai-based drugmaker, Lupin Atlantis Holdings SA in the District Court for the Eastern District of Pennsylvania. 

Lupin acquired rights to sell Antara in the world’s largest drug market from bankrupt American firm Oscient Pharmaceuticals in September 2009 for $38.61 million. Antara recorded net sales of $70 million in 2008. Lupin itself had challenged Oscient’s rights to sell Antara in the US before acquiring the drug. Fenofibrate products have a market of over $1.9 billion in the US. Antara has a small share of just around 5% and its sales are reportedly growing at around 20% a year.crackcrack

Lupin Share Price

2147.55 -14.65 (-0.68%)
20-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.50
Dr. Reddys Lab 1342.45
Cipla 1472.45
Lupin 2147.55
Zydus Lifesciences 973.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.